跳至主要内容
临床试验/NCT01878292
NCT01878292已完成3 期

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Forest Laboratories52 个研究点 分布在 1 个国家目标入组 529 人开始时间: 2013年7月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
529
试验地点
52
主要终点
Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score

研究概览

简要总结

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
12 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or Female outpatients between 12-17 years of age
  • Primary diagnosis of major depressive disorder (MDD)
  • Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater
  • Clinical Global Impressions-Severity (CGI-S) score of 4 or greater

排除标准

  • Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) based diagnosis of an axis disorder other than major depressive disorder (MDD) that is the primary focus of treatment.
  • History of suicidal behavior, or requires precaution against suicide
  • Not generally healthy medical condition
  • Seizure disorder

研究组 & 干预措施

Placebo

Placebo Comparator

Dose-matched placebo tablets, once per day, oral administration

干预措施: Placebo (Drug)

Vilazodone 15 mg

Experimental

15 mg vilazodone tablets, once per day, oral administration

干预措施: Vilazodone (Drug)

vilazodone 30 mg

Experimental

30 mg vilazodone tablets, once per day, oral administration

干预措施: Vilazodone (Drug)

结局指标

主要结局

Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score

时间窗: From Baseline to week 8

The Children's Depression Rating Scale-Revised (CDRS-R) total score ranges from 17 (minimal or no symptoms of depression) to 133 (indicative of depression) is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 to 17 years of age and their caregivers. The CDRS-R evaluates the presence and severity of symptoms commonly associated with depression in childhood.

次要结局

  • Change in Clinical Global Impressions-Severity (CGI-S) Score(From Baseline to Week 8)

研究者

发起方
Forest Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (52)

Loading locations...

相似试验